• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[恶性肿瘤药物治疗原则:细胞毒性药物疗效的决定因素]

[Principles of drug therapy of malignant tumors: determinants of the efficacy of cytostatic agents].

作者信息

Jeney A, Kralovánszky J

机构信息

I. sz. Pathologiai és Kísérleti Rákkutató Intézet, Semmelweis Orvostudományi Egyetem, Budapest.

出版信息

Orv Hetil. 1999 Jun 13;140(24):1339-45.

PMID:10439634
Abstract

Successful therapy with the anticancer cytostatic agents are remarkably dependent on the appropriate dosage and schedules of the treatment. To this end however it is highly important to have insights into the tumorbiological, pharmacokinetics, pharmacobiochemical and molecular-biological factors which underline the efficacy of the cytostatic agents. The present communication intend to provide a comprehensive survey for the medical doctors attending cancer patients concerning the mode of action of those anti tumour agents traditionally classified as alkylating agents, antimetabolites, topoisomerase inhibitors, and antimitotic agents. It will be emphasized that the currently available agents show no specific action on the malignant cells because they are inhibitors of cell proliferation and target certain molecular mechanism implicated in the cell cycle. The basis for the relatively selective antitumour action are rather different for the various cytostatic agents, nevertheless the differential activation and also the repair capacity in the tumour and in the normal organs offer an explanation for the agents acting directly or indirectly on DNA. Knowledge of the mode of action of the cytostatic agents offer not only a better understanding for their therapeutic failure but gives guidelines for those tumorbiological features which are necessary for their efficacy. In the last years substantial data have accumulated which indicate the possibility to improve the therapeutic action by modulating the pharmacokinetic or the pharmacobiochemical determinants of the antitumour drug action.

摘要

抗癌细胞抑制剂的成功治疗显著依赖于治疗的适当剂量和疗程。然而,为此深入了解肿瘤生物学、药代动力学、药物生物化学和分子生物学因素至关重要,这些因素是细胞抑制剂疗效的基础。本通讯旨在为治疗癌症患者的医生提供一份全面综述,内容涉及传统上归类为烷化剂、抗代谢物、拓扑异构酶抑制剂和抗有丝分裂剂的那些抗肿瘤药物的作用方式。需要强调的是,目前可用的药物对恶性细胞并无特异性作用,因为它们是细胞增殖抑制剂,靶向参与细胞周期的某些分子机制。各种细胞抑制剂相对选择性抗肿瘤作用的基础差异颇大,不过肿瘤和正常器官中的差异激活以及修复能力为这些药物直接或间接作用于DNA提供了解释。了解细胞抑制剂的作用方式不仅有助于更好地理解其治疗失败的原因,还能为其疗效所需的肿瘤生物学特征提供指导。近年来积累了大量数据,表明通过调节抗肿瘤药物作用的药代动力学或药物生物化学决定因素有可能提高治疗效果。

相似文献

1
[Principles of drug therapy of malignant tumors: determinants of the efficacy of cytostatic agents].[恶性肿瘤药物治疗原则:细胞毒性药物疗效的决定因素]
Orv Hetil. 1999 Jun 13;140(24):1339-45.
2
[Significance of the cell cycle for the effect of antineoplastic chemotherapy].[细胞周期在抗肿瘤化疗效果中的意义]
Acta Histochem Suppl. 1983;27:95-104.
3
[Principles of drug therapy of malignant tumors: the role of malignant progression in the choice of effective drugs].[恶性肿瘤药物治疗原则:恶性进展在有效药物选择中的作用]
Orv Hetil. 1999 May 30;140(22):1245-9.
4
[Cytostatic drugs--mechanism of action and guidelines for clinical use].[细胞毒性药物——作用机制与临床使用指南]
Fortschr Med. 1989 Oct 10;107(29):604-11.
5
Review: potential role of cell cycle synchronizing agents in combination treatment modalities of malignant tumors.综述:细胞周期同步剂在恶性肿瘤联合治疗模式中的潜在作用。
In Vivo. 2005 Jan-Feb;19(1):85-91.
6
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Semin Oncol. 1993 Oct;20(5 Suppl 7):2-12.
7
Endothelial cell effects of cytotoxics: balance between desired and unwanted effects.细胞毒性药物对内皮细胞的影响:预期效果与不良效果之间的平衡。
Cancer Treat Rev. 2004 Oct;30(6):495-513. doi: 10.1016/j.ctrv.2004.05.003.
8
Curative and palliative aspects of regional chemotherapy in combination with surgery.区域化疗联合手术的治疗与姑息治疗方面
Support Care Cancer. 2003 Jan;11(1):1-10. doi: 10.1007/s00520-002-0355-2. Epub 2002 Jun 8.
9
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
10
[Clinically important antineoplastic agents and risks and limits of their use].[临床重要的抗肿瘤药物及其使用风险与局限性]
Z Gesamte Inn Med. 1987 Jan 1;42(1):7-12.